This session will examine the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting
Tb-161, ongoing research to support the development of new radiopharmaceuticals, and how a sustainable supply of isotopes is being established to address the rapidly growing demands for clinicians and researchers.
Attendance is free to all attendees of the SNMMI Annual Meeting.
For more information or to register to attend SNMMI click here:
Session Moderator
General Manager, ITM USA
Expanding the use of theranostics & the clinical management of patients
Chief Medical Officer, UNITED THERANOSTICS
Growing Pipeline to Address Unmet Clinical Needs
Chief Medical Officer, ITM
Scalable Solutions to Meet the Rapidly Growing Needs
Chief Operating Officer, ITM
Session Moderator
General Manager, ITM USA
Expanding the use of theranostics & the clinical management of patients
Chief Medical Officer, UNITED THERANOSTICS
Growing Pipeline to Address Unmet Clinical Needs
Chief Medical Officer, ITM
Scalable Solutions to Meet the Rapidly Growing Needs
Chief Operating Officer, ITM
ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Germany
Email: info(at)itm-radiopharma.com
Phone: +49 89 329 8986 6000
Fax: +49 89 329 8986 6061
Bitte geben Sie Ihren Benutzernamen und Ihr Passwort ein, um sich an der Website anzumelden.
